DreamIt Health Philadelphia’s second class adds more life sciences startups

Featured Story

DreamIt Health Philadelphia’s second class adds more life sciences startups

July 18, 2014 8:38 am by | 0 Comments

DreamIt Ventures is kicking off its second health IT accelerator class in Philadelphia with a stronger life sciences theme than last year. More hospitals reviewed candidates this year and the…


Ties between industry & academia deepen as 7 pharmas offer ‘deprioritized’ drugs for research

Ties between industry & academia deepen as 7 pharmas offer ‘deprioritized’ drugs for research

July 22, 2014 2:22 pm by | 0 Comments

LONDON (Reuters) – A group of seven leading drugmakers has agreed to share an array of neglected experimental medicines with British academic researchers in the latest example of the deepening…


New Boehringer Ingelheim research alliance will search for new drug targets in the ubiquitin system

New Boehringer Ingelheim research alliance will search for new drug targets in the ubiquitin system

July 22, 2014 1:33 pm by | 0 Comments

German pharmaceutical group Boehringer Ingelheim said Tuesday it had entered into a research partnership with Canada’s University of Toronto via the Toronto Recombinant Antibody Centre (TRAC), along with Toronto-based University…



Celgene cancer drug may be able to wake up dormant HIV so it can be detected

Celgene cancer drug may be able to wake up dormant HIV so it can be detected

July 22, 2014 12:24 pm by | 0 Comments

LONDON (Reuters) – An anti-cancer drug made by the U.S. biotech firm Celgene can re-activate hidden HIV in patients so that it can be detected, bringing researchers closer to being…


Advaxis, MedImmune launch immunotherapy combo study in HPV-related cancers

Advaxis, MedImmune launch immunotherapy combo study in HPV-related cancers

July 22, 2014 11:00 am by | 0 Comments

US cancer immunotherapies developer Advaxis (NASDAQ:ADXS) said today it had partnered with MedImmune, the biologics unit of Anglo-Swedish AstraZeneca (LON:AZN, STO:AZN), to carry out a Phase I/II immunotherapy trial to…


GSK/Pfizer’s two-drug HIV regimen falls short in Phase 3 trial

GSK/Pfizer’s two-drug HIV regimen falls short in Phase 3 trial

July 22, 2014 10:40 am by | 0 Comments

ViiV Healthcare, a joint venture between UK GlaxoSmithKline plc (LON:GSK) and US Pfizer (NYSE:PFE), said Tuesday that a Phase III trial of maraviroc (MVC) once daily plus darunavir/ ritonavir (DRV/r)…


Who’s got eyes on Paxil and GSK’s other drugs up for bid? Sources say Indian & U.S. pharmas

Who’s got eyes on Paxil and GSK’s other drugs up for bid? Sources say Indian & U.S. pharmas

July 22, 2014 8:57 am by | 0 Comments

LONDON/MUMBAI (Reuters) – Indian generics firm Lupin, some U.S. drugmakers looking for a tax-saving deal in Europe and private equity funds are planning to bid for a range of older…


ViaCyte asks FDA for go-ahead with human trials of cell replacement therapy for diabetes

ViaCyte asks FDA for go-ahead with human trials of cell replacement therapy for diabetes

July 21, 2014 1:41 pm by | 0 Comments

ViaCyte, a privately held regenerative medicine company developing a cell replacement therapy for the treatment of diabetes, has filed an Investigational New Drug application with the United States Food and…



Report: Weight-loss drug banned in U.S. still causing life-threatening reactions in UK

Report: Weight-loss drug banned in U.S. still causing life-threatening reactions in UK

July 21, 2014 12:42 pm by | 0 Comments

NEW YORK (Reuters Health) – Use of a diet drug known as DNP has been linked to five deaths in the UK since 2007, according to a new report. The…


Ignyta launches clinical trials for metastatic cancer drug

Ignyta launches clinical trials for metastatic cancer drug

July 21, 2014 12:20 pm by | 0 Comments

US oncology biotech firm Ignyta Inc (NASDAQ:RXDX) said Monday it had begun a Phase I/II study of its oral tyrosine kinase inhibitor, RXDX-101, for the treatment of adults with locally…


Pfizer acquires drug development company with 30+ injectable eye products in the works

Pfizer acquires drug development company with 30+ injectable eye products in the works

July 21, 2014 9:39 am by | 0 Comments

United States-based Pfizer has signed a contract to acquire InnoPharma, a United States-based pharmaceutical development company, it was reported on Friday. The transaction is valued at USD360m. Under the deal,…


Shire confirms in talks with AbbVie on takeover bid

Shire confirms in talks with AbbVie on takeover bid

July 18, 2014 5:35 pm by | 0 Comments

(Reuters) – Shire Plc on Friday confirmed it has held a meeting with U.S. drugmaker AbbVie Inc to discuss AbbVie’s takeover bid for the Dublin-based maker of drugs for rare…


New Geisinger partnership will help build bigger biobank of tumor samples

New Geisinger partnership will help build bigger biobank of tumor samples

July 18, 2014 2:32 pm by | 0 Comments

Geisinger Health System is launching a partnership with Indivumed to bank and quickly preserve samples from consenting cancer patients undergoing surgical tumor removal. A developer for individualized oncology technology, Indivumed…


Heart patients with low health literacy may be more prone to medication errors after discharge

Heart patients with low health literacy may be more prone to medication errors after discharge

July 18, 2014 12:36 pm by | 0 Comments

NEW YORK (Reuters Health) – More than half of heart patients in a new U.S. study made mistakes taking their medications or misunderstood instructions given to them after being discharged…


Genmab, Janssen prep for third Phase 3 trial of ‘breakthrough’ multiple myeloma therapy

Genmab, Janssen prep for third Phase 3 trial of ‘breakthrough’ multiple myeloma therapy

July 18, 2014 11:47 am by | 0 Comments

Danish biotech group Genmab A/S (CPH:GEN) said Friday that its collaborator Janssen Biotech Inc, part of US Johnson & Johnson (NYSE:JNJ), intends to launch a Phase III study of daratumumab…


Kidney disease patients see benefits from Amgen parathyroid medicine in late-stage trial

Kidney disease patients see benefits from Amgen parathyroid medicine in late-stage trial

July 18, 2014 10:16 am by | 0 Comments

(Reuters) – An experimental drug proved effective in a late-stage study in reducing excess levels of a hormone associated with a serious condition often seen in patients with chronic kidney…